In the BioHarmony Drug Report Database
Victrelis (boceprevir) is a small molecule pharmaceutical. Boceprevir was first approved as Victrelis on 2011-05-13. It is used to treat chronic hepatitis c and hepatitis c in the USA. It is known to target lysosomal protective protein and Replicase polyprotein 1a. Victrelis’s patents are valid until 2027-11-11 (FDA).
Image (chem structure or protein)